High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families

Journal of Medical Genetics

Volumn 51, Issue 8, 2014, Pages 545-552

  Helgadottir, Hildur ^a   Höiom, Veronica ^a   Jönsson, Göran ^b   Tuominen, Rainer ^a   Ingvar, Christian ^b   Borg, Åke ^b   Olsson, Håkan ^b   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FAMILIAL CANCER; FEMALE; FIRST DEGREE RELATIVE; GENETIC ASSOCIATION; GENETIC RISK; GERMLINE MUTATION; HEAD AND NECK CARCINOMA; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; PANCREAS CARCINOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT CANCER; SECOND DEGREE RELATIVE; SMOKING; UPPER GASTROINTESTINAL TRACT; ADOLESCENT; ADULT; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NEOPLASMS; RISK; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROSPECTIVE STUDIES; RISK; SMOKING; YOUNG ADULT;

EID: 84905579541     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2014-102320     Document Type: Article

References (43)

1. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. New York: Grune & Stratton, 1979.
2. Skolnick MH, Cannon-Albright LA, Kamb A. Genetic predisposition to melanoma. Eur J Cancer 1994;30A:1991-5.
3. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in u.S. Melanoma-prone families with cdkn2a and cdk4 mutations. J Natl Cancer Inst 2000;92:1006-10.
4. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in cdkn2a mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
5. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. Screening of germline mutations in the cdkn2a and cdkn2b genes in swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
6. Hashemi J, Bendahl PO, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, Borg A. Haplotype analysis and age estimation of the 113insr cdkn2a founder mutation in swedish melanoma families. Genes Chromosomes Cancer 2001;31:107-16.
7. de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA. Increased risk of cancer other than melanoma in cdkn2a founder mutation (p16-leiden)-positive melanoma families. Clin Cancer Res 2008;14:7151-7.
8. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P, Bianchi-Scarra G. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83:441-8.
9. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16ink4 mutations. N Engl J Med 1995;333:970-4.
10. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA. Prospective risk of cancer in cdkn2a germline mutation carriers. J Med Genet 2004;41:421-4.
11. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M. Germ-line deletion involving the ink4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998;58:2298-303.
12. Cabanillas R, Astudillo A, Valle M, de la Rosa J, Alvarez R, Duran NS, Cadinanos J. Novel germline cdkn2a mutation associated with head and neck squamous cell carcinomas and melanomas. Head Neck 2013;35:E80-84.
13. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Melanoma Genetics C. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across genomel. Cancer Res 2006;66:9818-28.
14. Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B. Cdkn2a as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 2003;38:265-8.
15. Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in brca2, mmr and cdkn2a genes. Fam Cancer 2008;7:331-7.
16. Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB, Investigators GEMS. Risk of non-melanoma cancers in first-degree relatives of cdkn2a mutation carriers. J Natl Cancer Inst 2012;104:953-6.
17. Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, van den Ouweland A, Bakker E, Griffioen G, Devilee P, Cornelisse CJ, Meijers-Heijboer H, Vasen HF, Morreau H. Extending the p16-leiden tumour spectrum by respiratory tract tumours. J Med Genet 2004;41:e31.
18. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-leiden). Int J Cancer 2000;87:809-11.
19. Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH, Frucht H. Head and neck squamous cell carcinoma in fammm syndrome. Head Neck 2009;31:1524-7.
20. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, Melanoma Genetics C. Geographical variation in the penetrance of cdkn2a mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
21. Hansson J, Bergenmar M, Hofer PA, Lundell G, Mansson-Brahme E, Ringborg U, Synnerstad I, Bratel AT, Wennberg AM, Rosdahl I. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: Results of a swedish preventive program. J Clin Oncol 2007;25:2819-24.
22. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Lund Melanoma Study G, Melanoma Genetics C. Features associated with germline cdkn2a mutations: A genomel study of melanoma-prone families from three continents. J Med Genet 2007;44:99-106.
23. Statistics Sweden BF, Population and Welfare Statistics 2012:1, Multi-generation register 2011. A description of contents and quality. http://www.scb.se/statistik/_ publikationer/BE9999_2011A01_BR_BE96BR1202.pdf
24. Socialstyrelsen; Swedish cancer registry. http://www.Socialstyrelsen.Se/register/ halsodataregister/cancerregistret/inenglish
25. Goldstein AM. Familial melanoma, pancreatic cancer and germline cdkn2a mutations. Hum Mutat 2004;23:630.
26. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004;96:357-63.
27. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: Association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003;113:238-43.
28. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 2000;92:2037-9.
29. Sadler TW, Thomas W, Langman J. Langman's medical embryology. 11th edn. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins, 2010:275-319, 363-402.
30. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: Association by tumour type. J Intern Med 2002;252:206-24.
31. Pelucchi C, Tramacere I, Boffetta P, Negri E, La Vecchia C. Alcohol consumption and cancer risk. Nutr Cancer 2011;63:983-90.
32. McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, Petersen GM. Prevalence of cdkn2a mutations in pancreatic cancer patients: Implications for genetic counseling. Eur J Hum Genet 2011;19:472-8.
33. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45:478-86.
34. Carter H, Samayoa J, Hruban RH, Karchin R. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (chasm). Cancer Biol Ther 2010;10:582-7.
35. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS ONE 2012;7:e38892.
36. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
37. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT. P16(ink4a) and histology-specific methylation of cpg islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
38. Kraunz KS, McClean MD, Nelson HH, Peters E, Calderon H, Kelsey KT. Duration but not intensity of alcohol and tobacco exposure predicts p16ink4a homozygous deletion in head and neck squamous cell carcinoma. Cancer Res 2006;66:4512-15.
39. Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu K, Rios JJ, Yang C, Marconett CN, Selamat SA, Laird-Offringa IA, Taguchi A, Hanash S, Shames D, Ma X, Zhang MQ, Lam WL, Gazdar A. Cdkn2a/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol 2013;8:1378-88.
40. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(ink4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
41. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome I, Consortium IBC, Consortium IM-S, PedBrain I, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
42. Hocker T, Tsao H. Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants. Hum Mutat 2007;28:578-88.
43. Hoiom V, Tuominen R, Kaller M, Linden D, Ahmadian A, Mansson-Brahme E, Egyhazi S, Sjoberg K, Lundeberg J, Hansson J. Mc1r variation and melanoma risk in the swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res 2009;22:196-204.